As of 2026-09-11, the Intrinsic Value of Impel Neuropharma Inc (IMPL) is -115.47 USD. This IMPL valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.24 USD, the upside of Impel Neuropharma Inc is -47,992.16%.
Based on its market price of 0.24 USD and our intrinsic valuation, Impel Neuropharma Inc (IMPL) is overvalued by 47,992.16%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -115.47 - -115.47 | -115.47 | -47,992.16% |
| P/E | (545.01) - (547.32) | (574.45) | -238364.0% |
| DDM - Stable | (13.28) - (24.94) | (19.11) | -8025.1% |
| DDM - Multi | (3.59) - (5.54) | (4.37) | -1911.2% |
| Market Cap (mil) | 0.96 |
| Beta | 3.54 |
| Outstanding shares (mil) | 3.97 |
| Enterprise Value (mil) | -14.24 |
| Market risk premium | 5.00% |
| Cost of Equity | 106.54% |
| Cost of Debt | 5.00% |
| WACC | 5.68% |